{"title":"Late-Onset Oral Cenesthopathy With Dopaminergic Dysfunction: Therapeutic Response to Pramipexole in a Case With Suspected Prodromal Lewy Body Disease.","authors":"Hitomi Matsui, Takehiro Tamura, Masashi Kameyama, Yuki Omori, Genichi Sugihara, Takashi Takeuchi, Hidehiko Takahashi, Ko Furuta","doi":"10.1111/psyg.70088","DOIUrl":null,"url":null,"abstract":"<p><p>An 85-year-old woman with late-onset depression subsequently developed persistent oral cenesthopathy. As antidepressant augmentation, low-dose aripiprazole improved both mood and oral symptoms, but oversedation and parkinsonism necessitated tapering and discontinuation. After discontinuation, oral cenesthopathy recurred without clear depressive worsening. Dopamine transporter single-photon emission computed tomography showed reduced bilateral striatal uptake and <sup>123</sup>I-metaiodobenzylguanidine cardiac scintigraphy showed decreased uptake, with preserved cognition. In light of the clinical and imaging findings suggestive of dopaminergic dysfunction, and after an informed discussion of off-label use, pramipexole 0.25 mg daily was initiated. Oral discomfort lessened within 1 week and oral intake normalised by 2 weeks, without adverse effects; remission of oral symptoms and mood persisted for 6 months. Overall, the presentation was conceptually compatible with the psychiatric-onset phenotype described in the prodromal Lewy body disease research framework, but this remains an interpretive consideration rather than a diagnosis. Assessing possible dopaminergic involvement in similar cases of oral cenesthopathy may aid individualised management; however, the therapeutic role of dopamine agonists requires confirmation in prospective studies.</p>","PeriodicalId":74597,"journal":{"name":"Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society","volume":"25 5","pages":"e70088"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381603/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/psyg.70088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
An 85-year-old woman with late-onset depression subsequently developed persistent oral cenesthopathy. As antidepressant augmentation, low-dose aripiprazole improved both mood and oral symptoms, but oversedation and parkinsonism necessitated tapering and discontinuation. After discontinuation, oral cenesthopathy recurred without clear depressive worsening. Dopamine transporter single-photon emission computed tomography showed reduced bilateral striatal uptake and 123I-metaiodobenzylguanidine cardiac scintigraphy showed decreased uptake, with preserved cognition. In light of the clinical and imaging findings suggestive of dopaminergic dysfunction, and after an informed discussion of off-label use, pramipexole 0.25 mg daily was initiated. Oral discomfort lessened within 1 week and oral intake normalised by 2 weeks, without adverse effects; remission of oral symptoms and mood persisted for 6 months. Overall, the presentation was conceptually compatible with the psychiatric-onset phenotype described in the prodromal Lewy body disease research framework, but this remains an interpretive consideration rather than a diagnosis. Assessing possible dopaminergic involvement in similar cases of oral cenesthopathy may aid individualised management; however, the therapeutic role of dopamine agonists requires confirmation in prospective studies.